Section 1 - CHEMICAL PRODUCT AND COMPANY IDENTIFICATION

PRODUCT NAME

ZOLMITRIPAN

NFPA

PRODUCT USE

Acute treatment for migraine with or without aura. A selective agonist of 5-
hydroxytryptamine 1B/1D (5HT 1B/1D) receptor of the Triptan family. A specific and
selective 5- hydroxytryptamine- 1D- like receptor agonist with no effect on other 5HT
receptor subtypes. This receptor is found predominantly in cranial blood vessels. In
animals zolmitriptan selectively constricts the carotid arterial circulation which
supplies blood to the extracranial and intracranial tissues such as the meninges. Dilation
of these vessels is thought to be the underlying mechanism of migraine. May be given by
mouth or subcutaneously. WARNING: Drowsiness may occur as a result of treatment. Caution
is recommended when performing skilled tasks such as driving or operating machinery.

SYNONYMS

C16-H21-N3-O2, "2-oxazolidinone, 4-[(3-(2-(dimethylamino)ethyl)-1H-indol-5-yl)methyl]-,
(S)-", "2-oxazolidinone, 4-[(3-(2-(dimethylamino)ethyl)-1H-indol-5-yl)methyl]-, (S)-",
(S)-4-[(3-(2-(dimethylamino)ethyl)-1H-indol-5-yl)methyl]-2-oxazolidinone, (S)-4-[(3-(2-
(dimethylamino)ethyl)-1H-indol-5-yl)methyl]-2-oxazolidinone, "Triptan family", BW-311C90,
311C90, Zomig, "5-hydroxytryptamine agonist (5-HT 1B/1D)/ anti-migraine", "5-
hydroxytryptamine agonist (5-HT 1B/1D)/ anti-migraine"

Section 2 - HAZARDS IDENTIFICATION

CANADIAN WHMIS SYMBOLS

EMERGENCY OVERVIEW

RISK

Harmful if swallowed.
Limited evidence of a carcinogenic effect.

POTENTIAL HEALTH EFFECTS

ACUTE HEALTH EFFECTS

SWALLOWED

  Accidental ingestion of the material may be harmful; animal experiments indicate that ingestion of less than 150 gram may be fatal or may produce serious damage to the health of the individual.  Considered an unlikely route of entry in commercial/industrial environments.  

EYE

  There is some evidence to suggest that this material can causeeye irritation and damage in some persons.  Because of their alkaline nature eye contact with oxazolidines may produces moderate to severe irritation depending on the duration of contact.  

SKIN

  The material is not thought to produce adverse health effects or skin irritation following contact (as classified using animal models). Nevertheless, good hygiene practice requires that exposure be kept to a minimum and that suitable gloves be used in an occupational setting.  Oxazolidines generally do not produce systemic harmful following skin contact but, because of their alkaline nature, may produce moderate to severe irritation. Dermal reactions may include necrosis, sloughing and scab formation.  

INHALED

  The material is not thought to produce adverse health effects or irritation of the respiratory tract (as classified using animal models). Nevertheless, good hygiene practice requires that exposure be kept to a minimum and that suitable control measures be used in an occupational setting.  Persons with impaired respiratory function, airway diseases and conditions such as emphysema or chronic bronchitis, may incur further disability if excessive concentrations of particulate are inhaled.  

CHRONIC HEALTH EFFECTS

  There has been concern that this material can cause cancer or mutations, but there is not enough data to make an assessment.  

  Limited evidence of a carcinogenic effect.  Limited evidence of a carcinogenic effect.  There is some evidence of genotoxicity. Studies in animals show that the  material produced no teratogenic effects.  Although oxazolidines are able to cross-link with dermal proteins, there is no indication,  at present, that they are dermal sensitisers.  Oral teratology studies indicate that foetal toxicity occurs occurs at maternally toxic doses but that birth defects are not a feature of exposure.  Oxazolidines are generally not mutagenic in a battery of tests designed to investigate this effect.  Because they occur as secondary and tertiary amines, the concomitant use of nitrates may result in the production of potentially carcinogenic N-nitrosoamines. There is no evidence available to suggest that oxazolidines constitute a class of carcinogenic substance.